ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
about
Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitisSafety of monoclonal antibodies for the treatment of multiple sclerosis.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.
P2860
ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
ALAIN01--Alemtuzumab in autoim ...... and neuroprotective potential.
@ast
ALAIN01--Alemtuzumab in autoim ...... and neuroprotective potential.
@en
type
label
ALAIN01--Alemtuzumab in autoim ...... and neuroprotective potential.
@ast
ALAIN01--Alemtuzumab in autoim ...... and neuroprotective potential.
@en
prefLabel
ALAIN01--Alemtuzumab in autoim ...... and neuroprotective potential.
@ast
ALAIN01--Alemtuzumab in autoim ...... and neuroprotective potential.
@en
P2093
P2860
P50
P1433
P1476
ALAIN01--Alemtuzumab in autoim ...... and neuroprotective potential
@en
P2093
Ali Maisam Afzali
Karl-Friedrich Lukat
Luisa Klotz
Maria Eveslage
Nico Melzer
Steffen Pfeuffer
Sven G Meuth
Tobias Ruck
P2860
P2888
P356
10.1186/S12883-016-0556-9
P577
2016-03-10T00:00:00Z
P5875
P6179
1047714454